Omnicell (OMCL) Projected to Post Earnings on Thursday

Omnicell (NASDAQ:OMCL) will likely be issuing its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of $0.36 per share and revenue of $295.59 million for the quarter. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS.Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:30 AM ET.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The company had revenue of $290.56 million for the quarter, compared to the consensus estimate of $275.57 million. During the same quarter in the prior year, the business posted $0.51 EPS. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. On average, analysts expect Omnicell to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Omnicell Stock Down 1.8%

OMCL stock opened at $30.54 on Tuesday. The business has a 50 day moving average of $31.41 and a 200 day moving average of $30.18. The firm has a market cap of $1.40 billion, a PE ratio of 61.08, a price-to-earnings-growth ratio of 6.61 and a beta of 0.88. Omnicell has a twelve month low of $22.66 and a twelve month high of $55.74. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13.

Insider Buying and Selling

In other Omnicell news, EVP Corey J. Manley sold 3,880 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $33.25, for a total transaction of $129,010.00. Following the completion of the sale, the executive vice president directly owned 110,653 shares in the company, valued at approximately $3,679,212.25. The trade was a 3.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.52% of the company’s stock.

Institutional Trading of Omnicell

Several large investors have recently modified their holdings of the company. Thrivent Financial for Lutherans lifted its holdings in Omnicell by 1.2% in the second quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock valued at $1,013,000 after acquiring an additional 424 shares during the period. Public Sector Pension Investment Board lifted its stake in shares of Omnicell by 8.7% in the 2nd quarter. Public Sector Pension Investment Board now owns 159,658 shares of the company’s stock worth $4,694,000 after purchasing an additional 12,742 shares during the period. Headlands Technologies LLC boosted its holdings in shares of Omnicell by 1,865.0% in the second quarter. Headlands Technologies LLC now owns 18,137 shares of the company’s stock worth $533,000 after buying an additional 17,214 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Omnicell by 3.2% in the second quarter. CANADA LIFE ASSURANCE Co now owns 53,233 shares of the company’s stock worth $1,566,000 after buying an additional 1,638 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Omnicell by 385.5% during the second quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock valued at $146,000 after buying an additional 3,932 shares during the period. Institutional investors own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on OMCL shares. Weiss Ratings restated a “sell (d+)” rating on shares of Omnicell in a report on Wednesday, October 8th. Piper Sandler reduced their price objective on shares of Omnicell from $57.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 11th. Wall Street Zen downgraded shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 9th. Finally, Wells Fargo & Company raised their price target on shares of Omnicell from $37.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, July 21st. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Omnicell presently has a consensus rating of “Hold” and a consensus price target of $46.71.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.